Literature DB >> 6403772

A controlled, randomized trial evaluating the effects of enteral and parenteral nutrition on protein metabolism in cancer-bearing man.

M E Burt, T P Stein, M F Brennan.   

Abstract

To characterize the effects of enteral versus parenteral nutritional support on protein metabolism in the cancer patient, patients with localized, squamous cell carcinoma of the distal esophagus were randomized to receive nutritional support as follows: (1) if there was a loss of less than 20% of the preillness body weight, patients were randomized to continue eating ad libitum (group I) versus receiving total parenteral nutrition (TPN) (group II); (2) if there was a loss greater than 20% of the preillness body weight and/or the patient was unable to swallow, patients were randomized to jejunostomy feedings (group III) versus TPN (group IV). Patients were initially studied in the postabsorptive state and again 2 weeks after beginning, and while receiving, enteral or parenteral feedings. Stable isotopic tracer methods utilizing constant infusion of [15N]glycine were used to determine whole-body protein turnover (flux), synthesis, and catabolism. Skeletal muscle catabolism was determined by measuring the urinary excretion of 3-methylhistidine and lean tissue mass was evaluated by determining total-body potassium by 40K whole-body scanning. Positive nitrogen balance was obtained in groups II and IV associated with significant weight gain in both; the changes in weight were not significant in groups I and III. Whole-body protein flux increased in all groups, but significantly only in group II. Synthesis increased in groups II and IV and decreased in I and III, but not significantly. Catabolism tended to decrease in all groups but group I. Urinary 3-methylhistidine excretion decreased in groups II and IV signifying decreased skeletal muscle catabolism, but increased in groups I and III. Total body potassium tended to increase in groups II and IV. In this group of patients with localized squamous cell carcinoma of the esophagus, both TPN and jejunal feedings tended to stabilize nutritional status and whole-body protein economics. TPN appeared to be slightly more efficacious, although the differences between enteral and parenteral nutritional support in this study were slight.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403772     DOI: 10.1016/0022-4804(83)90076-8

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  Metabolic alteration in patients with cancer: nutritional implications.

Authors:  Y Sakurai; S Klein
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

2.  Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia.

Authors:  F Bozzetti; M Ammatuna; S Migliavacca; M G Bonalumi; G Facchetti; A Pupa; G Terno
Journal:  Ann Surg       Date:  1987-02       Impact factor: 12.969

3.  Metabolic effects of nutritional support to cancer patients.

Authors:  L Lindmark; L Ekman
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

4.  Protein synthesis in hepatocytes isolated from patients with gastrointestinal malignancy.

Authors:  H F Starnes; R S Warren; M F Brennan
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

Review 5.  Is enteral nutrition a primary therapy in cancer patients?

Authors:  F Bozzetti
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

Review 6.  Perioperative care of the oncology patient.

Authors:  C J Kelly; J M Daly
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

Review 7.  Nutritional support in patients with oesophageal cancer.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2009-06-24       Impact factor: 3.603

8.  A European survey on the practice of nutritional interventions in head-neck cancer patients undergoing curative treatment with radio(chemo)therapy.

Authors:  Federico Bozzetti; Cristina Gurizzan; Simon Lal; Andre' Van Gossum; Geert Wanten; Wojciech Golusinski; Sefik Hosal; Paolo Bossi
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-19       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.